

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:).	Examiner: Angell, Jon E.
Avi J. ASHKENAZI, et al.)	Art Unit: 1635
Application Serial No. 10/002,967)	Confirmation No. 5881
Filed: October 24, 2001)	Attorney's Docket No. 39780-2630 P1C72
For: SECRETED AND)	
TRANSMEMBRANE)	Customer No. 35489
POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME)	

EXPRESS MAIL LABEL NO. EV 582 625 049 US

Date Mailed: October 5, 2005

AMENDMENT AND RESPONSE TO OFFICE ACTION

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Office Action mailed on July 5, 2005 (Paper No./Mail Date 20050602), in connection with the above-identified patent application, please enter the following amendments, and consider the following arguments. This response is timely filed within the three month shortened statutory period set for the response.

Also filed herewith is an Information Disclosure Statement providing additional identifying information regarding the BLAST results. Applicants respectfully request that the information listed in the Information Disclosure Statement be considered by the Examiner and be made of record in the above-identified application.

The present Amendment and Response is further accompanied by the submission of a non-executed Declaration under 37 C.F.R. §1.131, the consideration of which is respectfully requested. The executed Declaration signed by all of the inventors will be submitted to the PTO shortly.

In addition, enclosed herewith is an Amendment under 37 C.F.R. §1.48(b) to correct the inventorship in the present application, the consideration of which is respectfully requested.

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Claims begin on page 12 of this paper.

Remarks/Arguments begin on page 18 of this paper.